Opinion

Video

Long-Term Safety of Second-Line Therapies for PBC

Panelists discuss how long-term safety monitoring for second-line primary biliary cholangitis (PBC) therapies requires systematic assessment of liver function, lipid profiles, and potential drug-specific adverse effects while emerging 5-year safety data for seladelpar continues to demonstrate a favorable risk profile compared with other treatment options.

Video content above is prompted by the following:

  1. What are the potential risks of long-term therapy with seladelpar, elafibranor, and obeticholic acid, and how can clinicians monitor for and mitigate these risks?
    1. Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
Related Videos
3 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video